GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » PE Ratio (TTM)

Moderna (Moderna) PE Ratio (TTM) : At Loss (As of May. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Moderna PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-20), Moderna's share price is $141.01. Moderna's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.67. Therefore, Moderna's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Moderna's PE Ratio (TTM) or its related term are showing as below:

MRNA' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 10.24   Max: 175.95
Current: At Loss


During the past 8 years, the highest PE Ratio (TTM) of Moderna was 175.95. The lowest was 0.00. And the median was 10.24.


MRNA's PE Ratio (TTM) is ranked worse than
100% of 248 companies
in the Biotechnology industry
Industry Median: 28.89 vs MRNA: At Loss

Moderna's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-3.07. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.67.

As of today (2024-05-20), Moderna's share price is $141.01. Moderna's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.57. Therefore, Moderna's PE Ratio without NRI for today is At Loss.

During the past 8 years, Moderna's highest PE Ratio without NRI was 176.38. The lowest was 0.00. And the median was 10.16.

Moderna's EPS without NRI for the three months ended in Mar. 2024 was $-3.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.57.

During the past 12 months, Moderna's average EPS without NRI Growth Rate was -233.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was -83.90% per year.

During the past 8 years, Moderna's highest 3-Year average EPS without NRI Growth Rate was -39.20% per year. The lowest was -83.90% per year. And the median was -42.50% per year.

Moderna's EPS (Basic) for the three months ended in Mar. 2024 was $-3.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-15.65.


Moderna PE Ratio (TTM) Historical Data

The historical data trend for Moderna's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna PE Ratio (TTM) Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial At Loss At Loss 8.98 8.93 At Loss

Moderna Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.27 44.83 At Loss At Loss At Loss

Competitive Comparison of Moderna's PE Ratio (TTM)

For the Biotechnology subindustry, Moderna's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Moderna's PE Ratio (TTM) falls into.



Moderna PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Moderna's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=141.01/-15.670
=At Loss

Moderna's Share Price of today is $141.01.
Moderna's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.67.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Moderna  (NAS:MRNA) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Moderna PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Moderna's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (Moderna) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Stephen Hoge officer: President C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel director, officer: Chief Executive Officer 320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres officer: See Remarks C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson officer: General Counsel and Secretary MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (Moderna) Headlines

From GuruFocus

Moderna Inc Science & Technology Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Vaccines Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc R&D Day Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024